Replies to post #28 on PharmaRoth Labs, Inc. (ROTH)

[Sportsjunkie]

SPAM SPAM SPAM...EVERYONE HAS ANOTHER NAME AS THE SENDER ON THE BOTTOM


Symbol - FROI
Current - .55
Short Target - 1.35+
Long Target - 3.80+
Rating - 10 of 10

With this $12 million acquisition, Fero is not only acquiring 11 promising new patents; the company is acquiring a virtual who?s who of expert management and scientific advisers in the space. Pyro strategy is to enter into either in-licensing or out-licensing agreements with major biotechnology or pharmaceutical companies later this year. Big pharmaceutical companies are projected to receive approximately 40% to 50% of their revenue from in-licensed products. Analysts say even a niche antibiotic can generate $200 million in annual sales worldwide; a powerful, broad-ranging drug could easily be a $1 billion product!

Fero?s aggressive synergistic growth through acquisition strategy for 2010 has already begun with initial negotiations, contact, and current due diligence taking place on two private and five public companies. Fero intends to parlay the Pyro acquisition by blending Pyro?s world class management team and future acquisitions to grow the companies both horizontally and vertically. Don?t miss out on this super gem in the making.

It's a stock-picker's moment if ever there were one. Pick the right needles out of this haystack and your portfolio doubles its worth. It's as simple as that. I only have time to tell a select few members about the breaking news that's got me excited again about investing in biotech stocks and in particular Fero Industries, Inc. (OTCBB: FROI - News). FROI?s first acquisition target is Pyro Pharmaceuticals, Inc., a boutique developmental stage drug pharmaceutical company located in Irvine, CA. Pyro?s focus is on developing a new class of antibiotics to fight drug resistant bacteria, such as MRSA.

Diamond in The Rough Equity Report

[nateeeeee]

Investor's Insight

Symbol - FROI
Current - .55
Short Target - 1.35+
Long Target - 3.80+
Rating - 10 of 10

With this acquisition, Fero (OTCBB: FROI - News) is not only acquiring 11 promising new patents; the company is acquiring a virtual who?s who of expert management and scientific advisers in the space. Pyro strategy is to enter into either in-licensing or out-licensing agreements with major biotechnology or pharmaceutical companies later this year. Big pharmaceutical companies are projected to receive approximately 40% to 50% of their revenue from in-licensed products. Analysts say even a niche antibiotic can generate $200 million in annual sales worldwide; a powerful, broad-ranging drug could easily be a $1 billion product! Pyro has also attracted impressive Scientific Advisory Board Members who have sat on various boards of industry giants such as: Merck, Glaxo, Vertex, Chiron, Abbott, Bristol Myers Squibb, Rhone-Poulenc Rorer, Hoechst Marion Roussel, and Cubist Pharmaceuticals, Inc. We?ve never seen such an impressive group of management and advisors in a company this size.

It's a stock-picker's moment if ever there were one. Pick the right needles out of this haystack and your portfolio doubles its worth. It's as simple as that. I only have time to tell a select few members about the breaking news that's got me excited again about investing in biotech stocks and in particular Fero Industries, Inc. (OTCBB: FROI - News). FROI?s first acquisition target is Pyro Pharmaceuticals, Inc., a boutique developmental stage drug pharmaceutical company located in Irvine, CA. Pyro?s focus is on developing a new class of antibiotics to fight drug resistant bacteria, such as MRSA.

One micro cap biotech, whose market cap is about to double, is ; Fero Industries, Inc. (OTCBB: FROI - News), the company recently disclose its growth strategy. FROI?s first acquisition target is Pyro Pharmaceuticals, Inc., a boutique developmental stage pharmaceutical company located in Irvine, CA. Pyro?s focus is on developing a new class of antibiotics to fight drug resistant bacteria, such as life-threatening MRSA. Today, infectious diseases are the leading cause of death worldwide and the third leading cause of death in the United States after cancer and heart disease and exceeding the totals deaths from AIDS. Pyro?s mission is clear and concise. The Company?s goal is to develop a new class of antibiotics to supplant the dwindling antibiotic arsenal.

Stock News Net